Analysts 16 incl. previous ratings
Rating Distribution 4 Buy · 10 Hold · 2 Sell
Date Action Analyst Rating Change Price Target Change Implied Upside Sep 08, 2026 Downgrade B BMO Capital Markets
Outperform → Market Perform $450 -3.5% Aug 05, 2026 Reiterated W Wells Fargo
Equal Weight $390 → $400 -14.2% Aug 05, 2026 Reiterated T Truist
Hold $340 → $362 -22.3% Aug 05, 2026 Reiterated R Robert W. Baird
Underperform $215 → $230 -50.7% Aug 05, 2026 Reiterated R RBC Capital Mkts
Outperform $370 → $400 -14.2% Aug 05, 2026 Reiterated O Oppenheimer
Outperform $400 → $450 -3.5% Aug 05, 2026 Reiterated M Morgan Stanley
Equal-Weight $333 → $351 -24.7% Aug 05, 2026 Reiterated C Canaccord Genuity
Hold $366 → $384 -17.6% Aug 05, 2026 Reiterated B BofA Securities
Underperform $312 → $317 -32.0% Aug 05, 2026 Reiterated B BMO Capital Markets
Outperform $400 → $450 -3.5% May 05, 2026 Downgrade E Erste Group
Buy → Hold Apr 21, 2026 Initiated C Canaccord Genuity
Hold $366 -21.5% Mar 10, 2026 Initiated J Jefferies
Hold $350 -24.9% Feb 20, 2026 Initiated B Barclays
Equal Weight $185 -60.3% Jan 20, 2026 Downgrade B Bernstein
Outperform → Mkt Perform $335 -28.1% Jan 07, 2026 Resumed U UBS
Buy $380 -18.5% Dec 05, 2025 Upgrade E Erste Group
Hold → Buy Nov 24, 2025 Resumed T Truist
Hold $318 -31.8% Nov 13, 2025 Initiated B Scotiabank
Sector Outperform $385 -17.4% Sep 03, 2025 Resumed R Raymond James
Mkt Perform
Show Previous Ratings
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Khosla Rachna SVP, Business Development Aug 13 '26 Option Exercise 162.60 1,252 203,575 7,656 Aug 13 07:05 PM Khosla Rachna SVP, Business Development Aug 11 '26 Sale 412.57 2,000 825,134 6,404 Aug 13 07:05 PM Khosla Rachna SVP, Business Development Aug 13 '26 Sale 416.43 1,252 521,365 6,404 Aug 13 07:05 PM Khosla Rachna Officer Aug 13 '26 Proposed Sale 412.76 1,252 516,775 Aug 13 11:14 AM Khosla Rachna Officer Aug 11 '26 Proposed Sale 414.21 2,000 828,420 Aug 11 03:40 PM Miller Derek SVP, Human Resources Aug 06 '26 Option Exercise 169.56 3,890 659,574 14,531 Aug 07 06:47 PM Miller Derek SVP, Human Resources Aug 06 '26 Sale 402.54 3,890 1,565,898 12,462 Aug 07 06:47 PM Grygiel Nancy A. SVP & CCO Aug 06 '26 Option Exercise 177.41 2,970 526,906 9,310 Aug 07 06:45 PM Grygiel Nancy A. SVP & CCO Aug 06 '26 Sale 402.16 2,970 1,194,415 7,340 Aug 07 06:45 PM Derek Miller Officer Aug 06 '26 Proposed Sale 404.85 3,890 1,574,866 Aug 06 05:09 PM Grygiel Nancy A. Officer Aug 06 '26 Proposed Sale 447.17 2,670 1,193,940 Aug 06 02:13 PM Grygiel Nancy A. SVP & CCO May 04 '26 Sale 323.73 1,237 400,451 7,009 May 05 08:09 PM Grygiel Nancy A. Officer May 04 '26 Proposed Sale 323.73 1,237 400,450 May 04 04:05 PM Bradway Robert A Chairman, CEO and President Mar 04 '26 Option Exercise 156.35 119,782 18,727,916 576,928 Mar 06 07:32 PM Santos Esteban EVP, Operations Feb 26 '26 Option Exercise 169.19 54,792 9,270,143 107,119 Mar 02 07:20 PM Santos Esteban EVP, Operations Feb 26 '26 Sale 379.12 54,792 20,772,595 76,618 Mar 02 07:20 PM Santos Esteban Associate Feb 26 '26 Proposed Sale 379.12 54,792 20,772,598 Feb 27 12:20 PM Busch Matthew C. VP, Finance & CAO Feb 19 '26 Sale 375.79 1,000 375,790 3,423 Feb 20 07:43 PM Busch Matthew C. ASSOCIATED TO AFFILIATE Feb 19 '26 Proposed Sale 375.00 1,000 375,000 Feb 19 03:55 PM Grygiel Nancy A. SVP & CCO Nov 20 '25 Option Exercise 169.70 3,139 532,691 8,864 Nov 21 08:34 PM Grygiel Nancy A. SVP & CCO Nov 20 '25 Sale 337.26 3,139 1,058,667 7,225 Nov 21 08:34 PM Grygiel Nancy A. Officer Nov 20 '25 Proposed Sale 337.26 3,139 1,058,667 Nov 20 04:45 PM Khosla Rachna SVP, Business Development Nov 12 '25 Sale 336.24 890 299,256 7,082 Nov 13 07:29 PM Gordon Murdo EVP, Global Commercial Ops Nov 12 '25 Sale 336.83 6,879 2,317,071 41,923 Nov 13 07:28 PM Gordon Murdo Officer Nov 12 '25 Proposed Sale 337.23 6,879 2,319,805 Nov 12 03:02 PM Khosla Rachna Officer Nov 12 '25 Proposed Sale 337.42 890 300,304 Nov 12 02:50 PM
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.
Chairman & CEO Mr. Robert A. Bradway
Executive Vice President of Global Markets and Policy Mr. Murdo Gordon
Executive Vice President Mr. Peter H. Griffith
EVP of Research & Development Dr. James E. Bradner M.D.
Executive VP & CFO Mr. Thomas J. W. Dittrich